From “Botox in a bottle” to castor oil and face taping, Dermatology Times reviews the evidence behind 3 viral dermatology trends from October.
|Articles|June 27, 2022
The Mainstream Patient: June 27
Author(s)Linda Stocum, Associate Editor
This week's edition of the Mainstream Patients features stories about FDA's latest approval, abortion, and more.
Advertisement
In this week’s edition, Self explains different feet issues and InStyle talks scalp sunburns. Cosmopolitan treats pimples and Glamour talks an FDA approval. Elle explains the Supreme Court's Roe V. Wade decision and Allure discusses the viral TikTok trend to get rid of face lines.
Bad Feet Season Has Arrived—Here’s How to Deal
Scalp Sunburns Are No Joke — But Here's How to Deal
Blind Pimple: How to Get Rid of Acne Under the Skin, According to Experts
The FDA Has Approved Olumiant for the Treatment of Alopecia Areata
The Supreme Court Overturns Roe V. Wade, Ending The Constitutional Right To Abortion
Does the Viral Face Taping Trend Actually Smooth Fine Lines?
Advertisement
Related to this article
Dermatology PAs unpack 4 frightening skin care myths and trends, from sunscreen misinformation and citrus DIYs to overusing actives and beef tallow.
The approval expands the IL-23 inhibitor’s indications beyond moderate-to-severe plaque psoriasis to include adults with active psoriatic arthritis.
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of October.
Clinician FAQ on remibrutinib's FDA approval in symptomatic dermographism: RemIND efficacy, mechanism, safety, and supporting CSU evidence.
Elevate-Derm Summer 2026 faculty share practical lessons on hair loss exams, PIH, geriatric dermatology, and managing cholesterol rises on JAK inhibitors.
Atopic dermatitis care is evolving with flexible biologic dosing, expanded pediatric options, and novel oral, topical, and systemic therapies.
Updated SKYRIZI labeling allows clinicians to use clinical judgment when determining the need for TB evaluation before treatment.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Tildrakizumab for Active Psoriatic Arthritis
2
FAQ: Remibrutinib (Rhapsido) Becomes First FDA-Approved Treatment for a Chronic Inducible Urticaria
3
Improving Early Identification and Escalation of HS
4
How Approvals, Setbacks, and a Crowded Pipeline Are Reshaping the AD Treatment Landscape
5